Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Gisbert

Showing results (161-170 of 211) with videos related to

Pageof 22
Sort By:
Alimentary Pharmacology & Therapeutics|July 20, 2007
First-line triple therapy with levofloxacin for Helicobacter pylori eradicationJ P Gisbert, M Fernández-Bermejo, J Molina-Infante, et al.
European Journal of Gastroenterology & Hepatology|September 30, 1999
Re-treatment after Helicobacter pylori eradication failureJ P Gisbert, D Boixeda, F Bermejo, et al.
Alimentary Pharmacology & Therapeutics|May 18, 2012
High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication ratesJ Sánchez-Delgado, P García-Iglesias, M Castro-Fernández, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Intensification of infliximab therapy in Crohn's disease: efficacy and safetyM Chaparro, P Martínez-Montiel, M Van Domselaar, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 7, 2000
13C-urea breath test for the diagnosis of Helicobacter pylori infection before treatment: is citric acid necessary?J P Gisbert, M A Vazquez, I Jimenez, et al.
Alimentary Pharmacology & Therapeutics|May 28, 2011
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's diseaseJ Panés, R Bouzas, M Chaparro, et al.
Alimentary Pharmacology & Therapeutics|February 26, 2010
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradicationJ Molina-Infante, B Perez-Gallardo, M Fernandez-Bermejo, et al.
The American Journal of Gastroenterology|May 15, 2019
Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic CancersMíriam Mañosa, M Chaparro, A Juan, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3)C Loras, J P Gisbert, M C Saro, et al.
Alimentary Pharmacology & Therapeutics|March 1, 2012
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failuresJ P Gisbert, M Castro-Fernandez, A Perez-Aisa, et al.
Pageof 22

Showing results (161-170 of 211) with videos related to

Sort By:
Pageof 22
Alimentary Pharmacology & Therapeutics|July 20, 2007
First-line triple therapy with levofloxacin for Helicobacter pylori eradicationJ P Gisbert, M Fernández-Bermejo, J Molina-Infante, et al.
European Journal of Gastroenterology & Hepatology|September 30, 1999
Re-treatment after Helicobacter pylori eradication failureJ P Gisbert, D Boixeda, F Bermejo, et al.
Alimentary Pharmacology & Therapeutics|May 18, 2012
High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication ratesJ Sánchez-Delgado, P García-Iglesias, M Castro-Fernández, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Intensification of infliximab therapy in Crohn's disease: efficacy and safetyM Chaparro, P Martínez-Montiel, M Van Domselaar, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 7, 2000
13C-urea breath test for the diagnosis of Helicobacter pylori infection before treatment: is citric acid necessary?J P Gisbert, M A Vazquez, I Jimenez, et al.
Alimentary Pharmacology & Therapeutics|May 28, 2011
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's diseaseJ Panés, R Bouzas, M Chaparro, et al.
Alimentary Pharmacology & Therapeutics|February 26, 2010
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradicationJ Molina-Infante, B Perez-Gallardo, M Fernandez-Bermejo, et al.
The American Journal of Gastroenterology|May 15, 2019
Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic CancersMíriam Mañosa, M Chaparro, A Juan, et al.
Journal of Crohn'S & Colitis|July 24, 2014
Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3)C Loras, J P Gisbert, M C Saro, et al.
Alimentary Pharmacology & Therapeutics|March 1, 2012
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failuresJ P Gisbert, M Castro-Fernandez, A Perez-Aisa, et al.
Pageof 22